Elanco Animal Health Competitors

Vertex Pharmaceuticals (NASDAQ:VRTX) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Vertex Pharmaceuticals and Elanco Animal Health, as provided by MarketBeat.com.

Vertex Pharmaceuticals currently has a consensus price target of $293.4737, suggesting a potential upside of 37.85%. Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Elanco Animal Health.

Profitability

This table compares Vertex Pharmaceuticals and Elanco Animal Health's net margins, return on equity and return on assets.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Elanco Animal Health on 14 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Regeneron Pharmaceuticals and Elanco Animal Health, as provided by MarketBeat.com.

Regeneron Pharmaceuticals currently has a consensus price target of $656.3810, suggesting a potential upside of 30.66%. Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Regeneron Pharmaceuticals is more favorable than Elanco Animal Health.

Profitability

This table compares Regeneron Pharmaceuticals and Elanco Animal Health's net margins, return on equity and return on assets.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Elanco Animal Health. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Elanco Animal Health on 12 of the 14 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Takeda Pharmaceutical and Elanco Animal Health, as provided by MarketBeat.com.

Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Takeda Pharmaceutical.

Profitability

This table compares Takeda Pharmaceutical and Elanco Animal Health's net margins, return on equity and return on assets.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Takeda Pharmaceutical and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Takeda Pharmaceutical has higher revenue and earnings than Elanco Animal Health. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Takeda Pharmaceutical has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Summary

Takeda Pharmaceutical beats Elanco Animal Health on 8 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Alexion Pharmaceuticals and Elanco Animal Health, as provided by MarketBeat.com.

Alexion Pharmaceuticals currently has a consensus price target of $159.3158, suggesting a potential downside of 7.27%. Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Alexion Pharmaceuticals and Elanco Animal Health's net margins, return on equity and return on assets.

Institutional & Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Alexion Pharmaceuticals and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Elanco Animal Health. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Elanco Animal Health on 11 of the 14 factors compared between the two stocks.

BeiGene (NASDAQ:BGNE) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for BeiGene and Elanco Animal Health, as provided by MarketBeat.com.

BeiGene currently has a consensus price target of $317.1250, suggesting a potential upside of 4.55%. Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given BeiGene's stronger consensus rating and higher probable upside, research analysts clearly believe BeiGene is more favorable than Elanco Animal Health.

Profitability

This table compares BeiGene and Elanco Animal Health's net margins, return on equity and return on assets.

Institutional & Insider Ownership

60.7% of BeiGene shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 9.0% of BeiGene shares are held by company insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares BeiGene and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Elanco Animal Health has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BeiGene has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Summary

Elanco Animal Health beats BeiGene on 8 of the 14 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Elanco Animal Health (NYSE:ELAN) are both large-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Royalty Pharma and Elanco Animal Health, as provided by MarketBeat.com.

Royalty Pharma currently has a consensus price target of $51.8750, suggesting a potential upside of 25.03%. Elanco Animal Health has a consensus price target of $31.8636, suggesting a potential downside of 1.17%. Given Royalty Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Royalty Pharma is more favorable than Elanco Animal Health.

Profitability

This table compares Royalty Pharma and Elanco Animal Health's net margins, return on equity and return on assets.

Institutional & Insider Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by company insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Royalty Pharma and Elanco Animal Health's top-line revenue, earnings per share and valuation.

Elanco Animal Health has higher revenue and earnings than Royalty Pharma.

Summary

Elanco Animal Health beats Royalty Pharma on 5 of the 9 factors compared between the two stocks.